2023 international evidence-based guideline pcos glp-1 receptor agonist on the Assessment and Management of #PCOS being presented at #ENDO2023 ⁦🤩 @TheEndoSociety⁩ in Chicago, IL 🇺🇸 Recommendations from the 2023 International

Description

doi: 10.1152/ajpgi.1988.255.3.G298

[DOI] [PubMed] [Google Scholar] 137.Nauck M.A., Friedrich N

There are several reasons why someone might choose to take GLP drugs, ranging from goals such as weight loss and improved heart health, to medical conditions like type 2 diabetes

These mechanisms occur within hours after GCs administration and may lead to hyperglycemia, even in individuals without a prior history of glucose abnormalities ( Figure 1 The clinical impact of hyperglycemia during GCs therapy has been well established, with multiple studies reporting increased morbidity and mortality, including higher rates of infection, cardiovascular events and prolonged hospitalisations ( Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are not currently recommended in SID by major guidelines, their mechanism of action makes them promising candidates to counteract the metabolic impacts of steroids